secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001493152-24-042741
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan
---------------------------------------------------------------------------

- Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.
- NDPD holds patents for ProLectin-M (COVID-19, RSV, H1N1, etc.) and a license agreement valued at $8.19M.
- CFO Ola Soderquist adopted 10b5-1 plan to sell up to 500,000 common shares through March 31, 2025.
- Consideration includes 14.1M Bioxytran preferred shares returned to treasury with a $4.0M book value.
- Goodwill of $5.38M recorded; intangible assets amortized over 18 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315224042741/0001493152-24-042741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315224042741/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer